AbbVie’s Skyrizi sustains clinical and endoscopic outcomes in ulcerative colitis for up to three years

By Public Technologies
  • AbbVie will present 20 inflammatory bowel disease research abstracts at UEG Week, Oct. 17-20, 2026, in Barcelona.
  • Skyrizi maintained clinical and endoscopic improvements in ulcerative colitis for up to three years; Rinvoq sustained Crohn's disease outcomes for approximately four years.
  • Real-world findings linked switching from TNF inhibitors to Rinvoq with fewer IBD-related hospitalizations or surgeries than cycling to another TNF inhibitor.
  • Upcoming Phase 3 AFFIRM presentations will expand findings on subcutaneous Skyrizi induction and maintenance in Crohn's disease.
  • Investigational dual-targeting therapy ABBV-466 will feature in a Phase 2a presentation on endoscopic remission in moderate-to-severe Crohn's disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610170200PR_NEWS_USPR_____CG73550) on October 17, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.